Abstract
BackgroundThree different mode of action of biologics (adalimumab, tocilizumab and abatacept) have been shown to provide clinical benefits in the patients (pts) who did not adequately respond to methotrexate (MTX-IR)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have